Probiotics Are Not Interchangeable: Strain Specificity Is the Whole Story

A probiotic product labeled “contains Lactobacillus rhamnosus” tells you almost nothing useful. The genus is Lactobacillus, the species is rhamnosus, and the strain is the part that actually determines what the bacteria does in your gut. Lactobacillus rhamnosus GG has been studied in over 800 clinical trials and has demonstrated effects on antibiotic-associated diarrhea, atopic dermatitis in children, and certain immune outcomes. Lactobacillus rhamnosus GR-1 is studied primarily in urogenital health. The two share a species name and produce different clinical effects through different mechanisms. They are not substitutes for each other.

The 2014 consensus statement from the International Scientific Association for Probiotics and Prebiotics, published in Nature Reviews Gastroenterology and Hepatology, made the strain specificity point as plainly as possible. Probiotic effects are strain-specific. Generalizing from one strain to another within the same species is not scientifically supported. The product label that lists only genus and species does not allow a consumer to map their purchase to the clinical evidence.

McFarland’s 2018 systematic review extended this practical implication. Of the probiotic strains with at least one positive randomized trial, the trials showed effects only for the specific clinical condition tested. A strain that helps with antibiotic-associated diarrhea cannot be assumed to help with irritable bowel syndrome. A strain that improves immune markers in elderly subjects cannot be assumed to do so in healthy adults. The mismatch between marketing claims and clinical evidence is largest in products that list strains without specifying the clinical indication those strains were studied for.

Suez and colleagues in Nature Medicine (2019) added a further complication. The same probiotic strain produces different effects in different individuals, partly determined by the recipient’s existing gut microbiome composition. Some individuals are resistant colonizers; others permit transient colonization. A probiotic that produces dramatic improvement in one trial subject may produce nothing measurable in another.

The practical translation is unromantic. A consumer interested in a specific outcome should look for products that list the exact strain studied for that outcome and match it to peer-reviewed trial evidence. Most do not. Most products list a multi-strain blend without specifying the strains, the clinical evidence base, or the colony-forming-unit count of each strain at end of shelf life. The blends are sold on the implicit assumption that more strains is better, which the actual research does not support. The honest version of probiotic advice begins with strain-level specificity, and most marketed products do not allow a consumer to act on it.